JP2017537084A - 抗エンドグリン抗体及びその用途 - Google Patents

抗エンドグリン抗体及びその用途 Download PDF

Info

Publication number
JP2017537084A
JP2017537084A JP2017525583A JP2017525583A JP2017537084A JP 2017537084 A JP2017537084 A JP 2017537084A JP 2017525583 A JP2017525583 A JP 2017525583A JP 2017525583 A JP2017525583 A JP 2017525583A JP 2017537084 A JP2017537084 A JP 2017537084A
Authority
JP
Japan
Prior art keywords
antibody
amino acid
antigen
fibrosis
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2017525583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537084A5 (enExample
Inventor
テウアー、チャールズ
Original Assignee
トラコン ファーマシューティカルズ、インコーポレイテッド
トラコン ファーマシューティカルズ、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トラコン ファーマシューティカルズ、インコーポレイテッド, トラコン ファーマシューティカルズ、インコーポレイテッド filed Critical トラコン ファーマシューティカルズ、インコーポレイテッド
Publication of JP2017537084A publication Critical patent/JP2017537084A/ja
Publication of JP2017537084A5 publication Critical patent/JP2017537084A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
JP2017525583A 2014-11-12 2015-11-11 抗エンドグリン抗体及びその用途 Ceased JP2017537084A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462078788P 2014-11-12 2014-11-12
US62/078,788 2014-11-12
PCT/US2015/060136 WO2016077451A1 (en) 2014-11-12 2015-11-11 Anti-endoglin antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2017537084A true JP2017537084A (ja) 2017-12-14
JP2017537084A5 JP2017537084A5 (enExample) 2018-08-23

Family

ID=55954987

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017525583A Ceased JP2017537084A (ja) 2014-11-12 2015-11-11 抗エンドグリン抗体及びその用途

Country Status (6)

Country Link
US (3) US10155820B2 (enExample)
JP (1) JP2017537084A (enExample)
AU (1) AU2015346444A1 (enExample)
CA (1) CA2966905A1 (enExample)
IL (1) IL251837A0 (enExample)
WO (1) WO2016077451A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2017037817A1 (ja) * 2015-08-31 2017-10-26 三菱電機株式会社 アプリケーション実行装置およびアプリケーション実行方法
WO2020022438A1 (ja) * 2018-07-26 2020-01-30 参天製薬株式会社 網膜線維化を伴う眼疾患の処置剤

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP3549952A1 (en) 2011-04-20 2019-10-09 Acceleron Pharma Inc. Endoglin polypeptides and uses thereof
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
EA202090707A1 (ru) * 2013-10-25 2020-12-30 Акселерон Фарма, Инк. Эндоглиновые пептиды для лечения фиброзных заболеваний
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2018187158A1 (en) * 2017-04-07 2018-10-11 Tracon Pharmaceuticals, Inc. Combination therapy of cancer with anti-endoglin antibodies and anti-programmed death receptor agents
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4602174A1 (en) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025122587A2 (en) * 2023-12-04 2025-06-12 Normunity, Inc. Anti-ly6k antibodies and methods of use
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506677A (ja) * 2009-09-30 2013-02-28 トラコン ファーマシューティカルズ、インコーポレイテッド エンドグリン抗体

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US928641A (en) 1908-10-09 1909-07-20 Levi E Edmunds Clasp for pilings.
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5308626A (en) 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20020136725A1 (en) 1996-01-17 2002-09-26 Smithkline Beecham Corporation Antithrombotic agents
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
ES2169864T3 (es) 1996-05-31 2002-07-16 Health Research Inc Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.
US6190660B1 (en) 1996-05-31 2001-02-20 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
US5796097A (en) 1997-03-05 1998-08-18 California Lightwave Laboratories, Inc. Chemical sensor and method
WO1998056418A1 (en) 1997-06-13 1998-12-17 Genentech, Inc. Stabilized antibody formulation
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
ATE400030T1 (de) 2001-02-19 2008-07-15 Merck Patent Gmbh Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenität
AU2002233343A1 (en) 2001-02-20 2002-09-24 Bayer Aktiengesellschaft Human transient receptor potential channel protein.
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
US20030003048A1 (en) 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
US20030124132A1 (en) 2001-09-27 2003-07-03 Board Of Regents, The University Of Texas System Combined compositions for tumor vasculature coaguligand treatment
US7115716B2 (en) 2001-11-19 2006-10-03 Eli Lilly And Company Tumor specific monoclonal antibodies
NZ534542A (en) 2002-02-14 2006-08-31 Chugai Pharmaceutical Co Ltd Antibody-containing solutions in which the formation of degradation products and insoluble particles during storage and freeze/thaw cycles is inhibited by adding a sugar and surfactant respectively
EP1494714A4 (en) 2002-04-05 2008-03-05 Amgen Inc HUMAN ANTI-OPGL NEUTRALIZING ANTIBODIES AS SELECTIVE OPGL PATH HEMMER
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7754884B2 (en) 2005-01-03 2010-07-13 Vanderbilt University Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging
US7217798B2 (en) 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
US7097836B1 (en) 2002-10-23 2006-08-29 Health Research, Inc. Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody
US7691374B2 (en) 2002-10-23 2010-04-06 Health Research, Inc. Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
US7120987B2 (en) 2003-08-05 2006-10-17 Avery Dennison Corporation Method of making RFID device
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2006226060A1 (en) 2005-03-25 2006-09-28 Glycart Biotechnology Ag Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US20100209437A1 (en) 2005-09-12 2010-08-19 Greg Elson Anti-CD3 Antibody Fromulations
US20070077310A1 (en) 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
US8142781B2 (en) 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
AU2007301599B2 (en) 2006-09-28 2013-01-10 Merck Serono S.A. Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use
AU2007307107B2 (en) 2006-10-06 2011-11-03 Amgen Inc. Stable antibody formulations
AR065092A1 (es) 2007-02-01 2009-05-13 Genentech Inc TERAPIA DE COMBINACIoN CON INHIBIDORES DE LA ANGIOGÉNESIS
US8748379B2 (en) 2007-06-06 2014-06-10 Research Development Foundation RTEF-1 variants and the use thereof for inhibition of angiogenesis
ES2396602T3 (es) 2007-09-14 2013-02-22 Bayer Intellectual Property Gmbh Compuestos tricíclicos sustituidos y procedimientos de uso de los mismos
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
RU2486200C2 (ru) 2008-01-14 2013-06-27 Дженентек, Инк. Способы ингибирования ангиогенеза с помощью антагонистов egfl8
WO2009139915A2 (en) 2008-05-15 2009-11-19 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
BRPI0918580B8 (pt) 2008-08-29 2021-05-25 Bayer Ip Gmbh polimorfo cristalino b da n-(2-aminofenil)-4-[n-(piridina3-il)metóxi-carbonilaminometil]-benzamida, composição e combinação contendo o mesmo, uso e seu processo de produção
US20100196398A1 (en) 2008-09-19 2010-08-05 Medimmune Llc Targeted binding agents directed to cd105 and uses thereof
US8699361B2 (en) 2008-09-30 2014-04-15 Qualcomm Incorporated Out-of-synchronization handling method and apparatus
US20100082438A1 (en) 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
TW201039854A (en) 2009-03-06 2010-11-16 Genentech Inc Antibody formulation
CN102711809B (zh) 2009-08-17 2015-09-30 特雷康制药公司 使用抗-内皮因子抗体和抗-vegf剂联合治疗癌症
US20180057602A1 (en) 2009-08-17 2018-03-01 Tracon Pharmaceuticals, Inc. Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
CA2803998A1 (en) 2010-07-02 2012-01-05 Medimmune, Llc Antibody formulations
EP3549952A1 (en) 2011-04-20 2019-10-09 Acceleron Pharma Inc. Endoglin polypeptides and uses thereof
US9468666B2 (en) 2011-08-01 2016-10-18 Tufts Medical Center, Inc. Treatment of heart failure and related conditions
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
US10214590B2 (en) 2013-09-20 2019-02-26 Tufts Medical Center, Inc. Inhibitors of endoglin activity for the treatment of fibrosis
GB201402009D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2018067819A1 (en) 2016-10-06 2018-04-12 Tracon Pharmaceuticals, Inc. Compositions and methods for treatment of cancers
WO2018187158A1 (en) 2017-04-07 2018-10-11 Tracon Pharmaceuticals, Inc. Combination therapy of cancer with anti-endoglin antibodies and anti-programmed death receptor agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506677A (ja) * 2009-09-30 2013-02-28 トラコン ファーマシューティカルズ、インコーポレイテッド エンドグリン抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF SURGERY, vol. 97, JPN6019033902, 2010, pages 892 - 901, ISSN: 0004106918 *
JOURNAL OF HEPATOLOGY, vol. 58, JPN6019033898, 2013, pages 60, ISSN: 0004106916 *
PLOS ONE, vol. 9(10), JPN6019033900, 14 October 2014 (2014-10-14), pages 110365 - 1, ISSN: 0004106917 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2017037817A1 (ja) * 2015-08-31 2017-10-26 三菱電機株式会社 アプリケーション実行装置およびアプリケーション実行方法
WO2020022438A1 (ja) * 2018-07-26 2020-01-30 参天製薬株式会社 網膜線維化を伴う眼疾患の処置剤

Also Published As

Publication number Publication date
US10336831B2 (en) 2019-07-02
CA2966905A1 (en) 2016-05-19
US10155820B2 (en) 2018-12-18
US20180312601A1 (en) 2018-11-01
IL251837A0 (en) 2017-06-29
AU2015346444A1 (en) 2017-05-04
US20190016815A1 (en) 2019-01-17
WO2016077451A1 (en) 2016-05-19
US20170335005A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
US10336831B2 (en) Use of anti-endoglin antibodies for treating ocular fibrosis
US9926375B2 (en) Anti-endoglin antibodies and uses thereof
US20250179199A1 (en) Antibodies to canine interleukin-4 receptor alpha
JP5896993B2 (ja) ヒトｇｄｆ８に対する抗体
US8999343B2 (en) Antibodies that bind myostatin, compositions and methods
KR102166083B1 (ko) 브라디키닌 b1 수용체 리간드에 대한 항체
JP2024054266A (ja) 組織因子経路インヒビター抗体およびその使用
US20170029513A1 (en) Methods of Improving or Accelerating Physical Recovery After Surgery for Hip Fracture
JP2020007354A (ja) 抗血漿カリクレイン抗体
KR20160042987A (ko) 산발성 봉입체 근염을 치료하는 방법
KR20220162819A (ko) 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
RS61431B1 (sr) Humanizovana antitela na tau u alchajmerovoj bolesti
KR20230109785A (ko) 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
KR101947758B1 (ko) 포스포릴콜린에 대한 신규 항체
KR20170016501A (ko) 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법
KR20230045613A (ko) Covid-19의 치료 및 예방을 위한 sars-cov-2 항체
EP4257195A2 (en) Anti-cfae antibodies and methods of use
WO2021190582A1 (zh) 一种抗ox40抗体药物组合物及其用途
US20240254219A1 (en) Novel wnt agonist antibodies and therapeutic uses thereof
JP2025523375A (ja) クローディン１８．２抗体、その製造方法及び使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200303

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200313

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20200729